Avistone Met inhibitor Phase I trial cleared for sites in Canada
The trial is already enrolling solid tumour patients in the US, with the FDA greenlighting the trial last year.
Immuno
Keytruda keys in on survival: Promising results in high-risk early-stage TNBC from KEYNOTE-522
ESMO 2024: Imfinzi to be practice changing in perioperative bladder cancer setting
ESMO 2024: Tecentriq/Avastin’s prospects as the first HCC adjuvant therapy fade
IN8bio cuts staff and pipeline to focus on AML cell therapy
UCLA Health to begin trial of personalised brain cancer vaccine
Ultimovacs cancer vaccine fails in Phase II trial for head and neck cancer
Immorna Biotherapeutics granted FDA IND clearance for Phase I/II JCXH-211 study
